Title:
RECOMBINANT POLYPEPTIDES CONTAINING AT LEAST ONE IMMUNOGENIC FRAGMENT AND ANTIBODY FC REGION AND USES THEREOF
Document Type and Number:
WIPO Patent Application WO/2022/006357
Kind Code:
A3
Abstract:
Provided is a recombinant polypeptide containing at least one immunogenic fragment of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) spike glycoprotein and an antibody Fc region. Also provided are a method for preventing, inhibiting, reducing, eliminating, protecting, or delaying the onset of an infection or an infectious clinical condition caused by a beta coronavirus in a subject which includes administering to the subject the recombinant polypeptide, and a method for inducing an immune response against a beta coronavirus in a subject, which includes administering to the subject the recombinant polypeptide.
Inventors:
SCHOMBURG FRITZ M (US)
RANCOUR DAVID M (US)
RANCOUR DAVID M (US)
Application Number:
PCT/US2021/040019
Publication Date:
February 10, 2022
Filing Date:
June 30, 2021
Export Citation:
Assignee:
BOOST BIOPHARMA INC (US)
International Classes:
C07K16/10; A61K39/15; A61K39/395
Foreign References:
| CN111337673A | 2020-06-26 |
Other References:
REN ET AL.: "Recombinant SARS-CoV-2 spike S1-Fc fusion protein induced high levels of neutralizing responses in nonhuman primates", VACCINE, vol. 38, no. 35, 1 July 2020 (2020-07-01) - 24 June 2020 (2020-06-24), pages 5653 - 5658, XP086216820, DOI: 10.1016/j.vaccine.2020.06.066
Attorney, Agent or Firm:
SCHUBERT, Michael J. (US)
Download PDF: